5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | SELL | SELL | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.32▲ | 2.32▲ | 2.32▲ | 2.36▲ | 2.31▲ |
MA10 | 2.32▲ | 2.30▲ | 2.30▲ | 2.34▲ | 2.35▲ |
MA20 | 2.32▲ | 2.37▼ | 2.37▼ | 2.31▲ | 2.18▲ |
MA50 | 2.40▼ | 2.39▼ | 2.36▼ | 2.35▲ | 3.22▼ |
MA100 | 2.36▼ | 2.50▼ | 2.40▼ | 2.14▲ | 3.13▼ |
MA200 | 2.77▼ | 2.46▼ | 2.68▼ | 3.05▼ | 3.08▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | -0.002▼ | -0.002▼ | 0.008▲ | 0.090▲ |
RSI | 50.287▲ | 49.303▼ | 49.604▼ | 52.599▲ | 46.628▼ |
STOCH | 56.504 | 45.585 | 45.585 | 63.823 | 36.009 |
WILL %R | -20.690▲ | -62.295 | -62.295 | -35.322 | -78.439▼ |
CCI | 84.542 | 48.522 | 48.522 | 89.187 | 18.002 |
Monday, April 28, 2025 01:44 PM
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...
|
Monday, April 28, 2025 06:30 AM
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...
|
Sunday, April 27, 2025 09:45 PM
Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 2.38 | 2.38 | 2.35 | 2.38 | 2,299 |
30/04/25 | 2.39 | 2.40 | 2.31 | 2.33 | 11,900 |
28/04/25 | 2.47 | 2.4783 | 2.35 | 2.40 | 5,166 |
25/04/25 | 2.39 | 2.39 | 2.3316 | 2.36 | 4,086 |
24/04/25 | 2.37 | 2.40 | 2.30 | 2.35 | 8,500 |
23/04/25 | 2.37 | 2.37 | 2.29 | 2.33 | 19,700 |
22/04/25 | 2.32 | 2.38 | 2.30 | 2.30 | 5,800 |
21/04/25 | 2.26 | 2.38 | 2.26 | 2.38 | 7,500 |
17/04/25 | 2.28 | 2.32 | 2.24 | 2.26 | 4,200 |
16/04/25 | 2.3048 | 2.38 | 2.2601 | 2.34 | 17,516 |
|
|
||||
|
|
||||
|
|